A key witness in the trial of Manabu Oshio testified Tuesday that he obtained and gave an illegal stimulant to the actor.

Yusuke Izumida went on to say Oshio later asked him to destroy any evidence of his illegal drug possession.

Oshio has been indicted for giving an illegal drug to Kaori Tanaka and for abandonment resulting in death after she died of an overdose while he did not call for medical help.

At the third session of the trial at the Tokyo District Court, Izumida, 32, testified that Oshio had asked him to obtain MDMA, commonly known as Ecstasy. Izumida said the drug was obtained a few days before Tanaka died Aug. 2, 2009, in an apartment in the Roppongi district.

Oshio has claimed that Tanaka brought the Ecstasy to the apartment and took it by herself. Oshio has admitted he obtained the same kind of drug from Izumida but claimed it was not the one the woman took at the apartment.

Later in the session, Oshio’s lawyers asked Izumida whether their client told him that evening that the drug that Tanaka took was the one Izumida obtained for him. Izumida said he didn’t.

According to Izumida, he received e-mails and phone calls that night from Oshio desperately asking for his help.

Izumida testified that when he arrived at the apartment he saw two of Oshio’s acquaintances urging Oshio to call an ambulance for Tanaka. Oshio refused because he didn’t want to be found in possession of the drugs, Izumida said.

Oshio also asked his manager to claim to have been the first to find Tanaka dead while they were all in a meeting in a different room in the same apartment complex, Izumida said.

He said Oshio handed him a plastic container with MDMA inside, apparently asking him to get rid of it.

“He told me, ‘these are it,’ ” Izumida said. “I thought I had to get rid of it for him.”

Izumida was called as a prosecution witness.

Oshio has pleaded not guilty to the main charges against him. The verdict is scheduled for Sept. 17.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.